ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > CCL22

CCL22

概要

Name:ATP Binding Cassette Subfamily D Member 1
Target Synonym:ATP Binding Cassette Subfamily D Member 1,Adrenoleukodystrophy Protein,ATP-Binding Cassette Sub-Family D Member 1,ALDP,ATP-Binding Cassette, Sub-Family D (ALD), Member 1,ABC42,ABCD1,AMN,ALD,ATP Binding Cassette Transporter, Subfamily D, Member 1,Adrenoleukodystrophy
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:2
Lastest Research Phase:Approved

製品リスト製品比較と製品注文

製品仕様別:
製品カテゴリー別:
種類別:
タグ別:
コンジュゲート:
製造番号 種類 製品説明 構造 純度 特徴
CC2-H5257 Human Human CCL22 / MDC Protein, Fc Tag
CC2-H5257-structure
CC2-H5257-sds
ACRO Quality

Synonym Name

MDC/ABCD-1/SCYA22/STCP-1/DC/B-CK/A-152E5.1

Background

This antimicrobial gene is one of several Cys-Cys (CC) cytokine genes clustered on the q arm of chromosome 16. Cytokines are a family of secreted proteins involved in immunoregulatory and inflammatory processes. The CC cytokines are proteins characterized by two adjacent cysteines. The cytokine encoded by this gene displays chemotactic activity for monocytes, dendritic cells, natural killer cells and for chronically activated T lymphocytes. It also displays a mild activity for primary activated T lymphocytes and has no chemoattractant activity for neutrophils, eosinophils and resting T lymphocytes. The product of this gene binds to chemokine receptor CCR4. This chemokine may play a role in the trafficking of activated T lymphocytes to inflammatory sites and other aspects of activated T lymphocyte physiology.

Clinical and Translational Updates

公開薬物情報

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Elivaldogene autotemcel Approved Bluebird Bio Inc, Inserm Lenti-D, Skysona United States Adrenoleukodystrophy Bluebird Bio Inc 2021-07-27 Adrenoleukodystrophy Details
Elivaldogene autotemcel Approved Bluebird Bio Inc, Inserm Lenti-D, Skysona United States Adrenoleukodystrophy Bluebird Bio Inc 2021-07-27 Adrenoleukodystrophy Details

臨床試験情報

Name Research Code Research Phase Company Indications Clinical Trials
Pozetaldogene ormesparvovec SBT-101 Phase 2 Clinical SwanBio Therapeutics Ltd Adrenoleukodystrophy Details
TYF-ABCD1 TYF-ABCD1 Clinical Shenzhen Geno-Immune Medical Institute Adrenoleukodystrophy Details
Pozetaldogene ormesparvovec SBT-101 Phase 2 Clinical SwanBio Therapeutics Ltd Adrenoleukodystrophy Details
TYF-ABCD1 TYF-ABCD1 Clinical Shenzhen Geno-Immune Medical Institute Adrenoleukodystrophy Details

This web search service is supported by Google Inc.

totopphone